A Randomized, Double-blind, Triple-dummy, Placebo Controlled, Single-dose, 4-way Crossover Study to Determine the Relative Abuse Potential of PF-00345439 (Oxycodone Extended Release Capsules) Compared to Immediate-release Oxycodone and Placebo When Administered Orally Whole And/or Chewed to Non-dependent, Recreational Opioid Users Under Fasted Conditions

Trial Profile

A Randomized, Double-blind, Triple-dummy, Placebo Controlled, Single-dose, 4-way Crossover Study to Determine the Relative Abuse Potential of PF-00345439 (Oxycodone Extended Release Capsules) Compared to Immediate-release Oxycodone and Placebo When Administered Orally Whole And/or Chewed to Non-dependent, Recreational Opioid Users Under Fasted Conditions

Completed
Phase of Trial: Phase I

Latest Information Update: 11 May 2016

At a glance

  • Drugs Oxycodone (Primary)
  • Indications Pain
  • Focus Pharmacodynamics; Registrational
  • Sponsors Pfizer
  • Most Recent Events

    • 11 May 2016 New data from this trial were presented at the 35th Annual Scientific Meeting of the American Pain Society (APS), according to a Pain Therapeutics media release.
    • 12 May 2015 Top-line results published in a Pain Therapeutics media release.
    • 12 May 2015 Primary endpoint of 'High: Area Under Effect Curve (AUE) From 0-2 Hours' has been met, according to a Pain Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top